Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37

Virology

Volumn 272, Issue 2, 2000, Pages 402-408

  Okamoto, Hiroshi ^a   Cujec, Thomas P ^b   Okamoto, Mika ^c   Peterlin, B Matija ^b   Baba, Masanori ^c   Okamoto, Takashi ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 (3,4 DEHYDRO 4 PHENYL 1 PIPERIDINYL) 1,4 DIHYDRO 6 FLUORO 1 METHYL 8 TRIFLUOROMETHYL 4 OXOQUINOLINE 3 CARBOXYLIC ACID; CYCLIN DEPENDENT KINASE; ELONGATION FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN U937; CONTROLLED STUDY; DRUG MECHANISM; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; TRANSACTIVATION; TRANSCRIPTION INITIATION; VIRUS INHIBITION;

EID: 0034608946     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0396     Document Type: Article

References (39)

1. Aso T., Lane W. S., Conaway J. W., Conaway R. C. Elongin (SIII): A multisubunit regulator of elongation by RNA polymerase II. Science. 269:1995;1439-1443.
2. Baba M., Okamoto M., Makino M., Kimura Y., Ikeuchi T., Sakaguchi T., Okamoto T. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob. Agents Chemother. 41:1997;1250-1255.
3. Baba M., Okamoto M., Kawamura M., Makino M., Higashida T., Takashi T., Kimura Y., Ikeuchi T., Tetsuka T., Okamoto T. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol. Pharmacol. 53:1998;1097-1103.
4. Braddock M., Thorburn A. M., Kingsman A. J., Kingsman S. M. Blocking of tat-dependent HIV-1 RNA modification by an inhibitor of RNA polymerase II processivity. Nature. 350:1991;439-441.
5. Cujec T., Okamoto H., Fujinaga K., Meyer J., Chamberlin J., Morgan D., Peterlin B. M. The HIV trans-activator Tat binds to the CDK-activating kinase (CAK) and activates the phosphorylation of the C-terminal domain of RNA polymerase II. Genes Dev. 11:1997;2645-2657.
6. Fisher R. P., Jin P., Chamberlin H. M., Morgan D. O. Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase. Cell. 83:1995;47-57.
7. Fujinaga K., Cujec T. P., Peng J., Garriga J., Price D. H., Grana X., Peterlin B. M. The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase, domain, cyclin T1, and Tat. J. Virol. 72:1998;7154-7159.
8. Garcia-Martinez L., Mavankal G., Neveu J., Lane W., Ivanov D., Gaynor R. Purification of a Tat-associatede kinase reveals a TFIIH complex that modulates HIV-1 transcription. EMBO J. 16:1997;2836-2850.
9. Ghosh S., Toth C., Peterlin B. M., Seto E. Synergistic activation of transcription by the mutant and wild-type minimal transcriptional activation domain of VP16. J. Biol. Chem. 271:1996;9911-9918.
10. Gold M. O., Yang X., Herrmann C. H., Rice A. P. PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo. J. Virol. 72:1998;4448-4453.
11. Hayashi T., Ueno Y., Okamoto T. Oxidoreductive regulation of nuclear factor κB. J. Biol. Chem. 268:1993;11380-11388.
12. Herrmann C. H., Rice A. P. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: Candidate for a Tat cofactor. J. Virol. 69:1995;1612-1620.
13. Hottiger M. O., Nabel G. J. Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J. Virol. 72:1998;8252-8256.
14. Hsu M., Schutt A. D., Holly M., Slice L. W., Sherman M. I., Richman D. D., Potash M. J., Volsky D. J. Inhibition of HIV replication in acute and chronic infections in vitro by a tat antagonist. Science. 254:1991;1799-1802.
15. Jeang K.-T., Xiao H., Rich E. A. Multifaced activities of the HIV-1 Tat transactivator of transcription, Tat. J. Biol. Chem. 274:1999;28837-28840.
16. Jones K. A. Taking a new TAK on Tat transactivation. Genes Dev. 11:1997;2593-2599.
17. Jones K. A., Peterlin B. M. Control of RNA initiation and elongation at the HIV-1 promoter. Annu.Rev.Biochem. 63:1994;717-743.
18. Kahn J. Tackling Tat. J. Mol. Biol. 293:1999;235-254.
19. Laspia M. F., Rice A. P., Mathews M. B. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell. 59:1989;283-292.
20. Mancebo H., Lee G., Flygare J., Tomassini J., Luu P., Zhu Y., Blau C., Hazyda D., Price D., Flores O. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 11:1997;2633-2644.
21. Marciniak R. A., Sharp P. A. HIV-1 Tat protein formation of more processive elongation complexes. EMBO J. 10:1991;4189-4196.
22. Marshall R. A., Peng J., Xie Z., Price D. H. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J. Biol. Chem. 271:1996;27176-27183.
23. Mavankal G., Ignatius Ou S. H., Oliver H., Sigman D., Gaynor R. B. Human immunodeficiency virus type 1 and 2 Tat proteins specifically interact with RNA polymerase II. Proc. Natl. Acad. Sci. USA. 93:1996;2089-2063.
24. Neuman J. R., Morency C. A., Russian K. O. A novel rapid assay for chloramphenicol acetyltransferase gene expression. Biotechniques. 5:1987;444-448.
25. Okamoto H., Sheline C., Corden J., Jones K., Peterlin B. M. Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II. Proc. Natl. Acad. Sci. USA. 93:1996;11575-11579.
26. Okamoto M., Okamoto T., Baba M. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells. Antimicrob. Agents Chemother. 43:1999;492-497.
27. Okamoto T. Regulatory proteins of human immunodeficiency virus and therapy. Mohan O., Baba M. Anti-AIDS Drug Depelopment; Challenges, Strategies and Prospects. 1995;117-127 Harwood Academic Publishers, Chur.
28. Okamoto T., Wong-Staal F. Demonstration of virus-specific transcriptionalactivator(s) in cells infected with HTLV-III by an in vitro cell-free system. Cell. 47:1986;29-36.
29. Parada C. A., Roeder R. G. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxyl-terminal domain. Nature. 384:1996;375-378.
30. Patturajan M., Schulte R. J., Sefton B. M., Berezney R., Vincent M., Bensaude O., Warren S. L., Corden J. L. Growth-related changes in phosphorylation of yeast RNA polymerase II. J. Biol. Chem. 273:1997;4689-4694.
31. Selby M. J., Bain E. S., Luciw P. A., Peterlin B. M. Structure, sequence, and position of the stem-loop in TAR determine transcriptional elongation by Tat through the HIV-1 long terminal repeat. Genes Dev. 3:1989;547-558.
32. Sharp P. A., Marciniak R. A. HIV TAR: An RNA enhancer? Cell. 59:1989;229-230.
33. Sodrodski J. G., Rosen C., Wong-Staal F., Salahuddin S. K., Popovic M., Arya S., Gallo R. C., Haseltine W. A. Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science. 227:1985;171-173.
34. Southgate C., Zapp M. L., Green M. R. Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein. Nature. 345:1990;640-642.
35. Wada T., Takagi T., Yamaguchi Y., Ferdous A., Imai T., Hirose S., Sugimoto S., Yano K., Hartzog G. A., Winston F., Buratowski S., Handa H. DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs. Genes Dev. 12:1998;343-356.
36. Wei P., Garber M. E., Fang S. M., Fischer W. H., Jones K. A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell. 92:1998;451-462.
37. Yamaguchi Y., Takagi Y., Wada T., Yano K., Furuya A., Sugimoto S., Hasegawa H., Handa H. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell. 97:1999;41-51.
38. Yang J.-P., Hori M., Sanda T., Okamoto T. Identification of a novel inhibitor of nuclear factor-κB, RelA-associated inhibitor (RAI). J. Biol. Chem. 274:1999;15662-15670.
39. Zhu Y., Pe'ery T., Peng J., Ramanathan Y., Marshall N., Marshall T., Amendt B., Mathews M., Price D. Transcriptional elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro. Genes Dev. 11:1997;2622-2633.